Researchers show how common mutation in SCLC makes mouse tumors more vulnerable to certain cancer drugs
Sept. 4, 2018
| By Sabrina Richards / Fred Hutch News Service
Work by Dr. David MacPherson could point the way toward a targeted treatment for a subset of small-cell lung cancers. He showed that SCLC tumors with a specific DNA mutation are more vulnerable to certain drugs.
Nine out of 10 patients treated with the experimental therapy saw their tumors shrink
April 13, 2018
| By Rachel Tompa / Fred Hutch News Service
When you look at Carla Stone, you might not guess that she was diagnosed with stage 4 head and neck cancer just two years ago. Stone participated in a clinical trial that shrank her advanced tumor down to nothing, allowing her to undergo a minimally invasive surgery.
Fred Hutch Pancreatic cancer researcher Dr. Sunil Hingorani has won a three-year, $1.8 million grant from the federal Cancer Moonshot program, the signature initiative of former Vice President Joseph Biden. Hingorani is one of six collaborators nationwide who received funding this fall for a new research consortium focused on the biological context of pancreatic tumors — such as nearby immune cells or blood vessels — which can have a major impact on a tumor’s vulnerability to treatment.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.